Excitement in the microbiome space has accelerated considerably in recent years, with research suggesting that microbiome-directed therapeutics could hold the key to treating a variety of health conditions, such as gastrointestinal, infectious, inflammatory, and metabolic diseases, oncology, as well as neurological disorders. Given this sizable opportunity, investment in microbiome-focused companies and initiatives continues to accelerate, including the $121 million National Microbiome Initiative commitment from the White House. With industry bellwethers recently entering late-stage clinical trials, investors are now seeking a better understanding of the microbiome, the therapeutic approaches that offer the greatest promise, and the technologies that have the potential to deliver evidence-based clinical outcomes. This panel will feature discussions about current experiences in microbiome drug development and the promising future of microbiome therapies, including the risks and rewards.

Ability Level: Advanced

Session ID: 19652